Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VASIS-1: Pilot study of 0.2% sirolimus gel in vascular abnormalities without effective therapy
jRCTs051190032Completed
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sirolimus in vascular malformation, hemangioma, lymphangioma and 1 more. Primary endpoint: Safety: incidence of adverse events related to sirolimus gel. Started Jul 2019; status: completed.
02
Drugs
sirolimus
03
Conditions
vascular malformationhemangiomalymphangiomavascular abnormality
Beyond the preview
Go deeper on jRCTs051190032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051190032.